Get the Stockscreener App
23.82
0.17%
-0.04
After Hours:
23.74
-0.08
-0.34%
Lb Pharmaceuticals Inc stock is traded at $23.82, with a volume of 258.18K.
It is down -0.17% in the last 24 hours and up +19.76% over the past month.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
See More
Previous Close:
$23.86
Open:
$24.03
24h Volume:
258.18K
Relative Volume:
0.93
Market Cap:
$602.62M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.05%
1M Performance:
+19.76%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.16
$24.53
1-Week Range:
$20.65
$24.95
52-Week Range:
$13.36
$24.95
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
23.82 | 603.64M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Roth Capital | Buy |
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
LB Pharmaceuticals announces $100.0 million private placement - marketscreener.com
LB Pharmaceuticals Announces $100 Million Private Placement Financing - TipRanks
LB Pharmaceuticals Signs Multiple Material Agreements - TradingView
Lb Pharmaceuticals Announces $100.0 Million Private Placement - TradingView
LB Pharmaceuticals Announces $100.0 Million Private Placement - The Manila Times
LB Pharmaceuticals lines up $100M for new depression trial - stocktitan.net
Sector Update: Health Care - marketscreener.com
LB Pharmaceuticals Advances LB-102 Into Long-Term Phase 3 Safety Study for Schizophrenia - TipRanks
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug By Investing.com - Investing.com Australia
LB Pharmaceuticals initiates Phase 2 trial of LB-102 - Yahoo Finance
LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 6.4%Time to Sell? - MarketBeat
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug - Investing.com
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in - GlobeNewswire
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program - Sahm
LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighWhat's Next? - MarketBeat
LB Pharmaceuticals appoints Minako Pazdera as general counsel By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials - Investing.com
LB Pharmaceuticals appoints Minako Pazdera as general counsel - Investing.com
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel - manilatimes.net
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 5.5%What's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 7.7%Time to Buy? - MarketBeat
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LB Pharmaceuticals (NASDAQ:LBRX) Coverage Initiated at Roth Capital - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Roth Capital - MarketBeat
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential - Investing.com Australia
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential By Investing.com - Investing.com South Africa
PR News | On the Move: The Trevor Projects Names Wong CCOThu., Jan. 8, 2026 - O'Dwyer's PR
Poplar’s $50 million Series A to ‘transform treatment of atopic diseases’ - The Pharma Letter
LB Pharmaceuticals appoints two executives to leadership team By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Appoints Ellen Rose and Lindsay Beaupre as Senior Vice Presidents - citybiz
LB Pharmaceuticals appoints two executives to leadership team - Investing.com India
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture - The Manila Times
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
There is no financial data for Lb Pharmaceuticals Inc (LBRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):